Short Interest in Neuren Pharmaceuticals Limited (OTCMKTS:NURPF) Decreases By 13.9%

Neuren Pharmaceuticals Limited (OTCMKTS:NURPF) saw a large drop in short interest during the month of January. As of January 15th, there was short interest totalling 1,625,900 shares, a drop of 13.9% from the December 31st total of 1,887,800 shares. Based on an average daily volume of 100 shares, the days-to-cover ratio is currently 16,259.0 days.

Neuren Pharmaceuticals Price Performance

Shares of Neuren Pharmaceuticals stock remained flat at C$8.86 on Friday. Neuren Pharmaceuticals has a 1 year low of C$6.61 and a 1 year high of C$14.95. The company’s 50-day simple moving average is C$7.93 and its 200-day simple moving average is C$9.27.

Neuren Pharmaceuticals Company Profile

Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders. It develops and commercializes DAYBUE (trofinetide), which has been registered to treat Rett syndrome in adults and pediatric patients 2 years of age and older, as well as in Phase 2 clinical trial to treat Fragile X syndrome.